Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Finance

Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs

Biotech has aligned its internal focus on CAR NKs, but may partner elsewhere

January 6, 2021 11:14 PM UTC
Updated on Jan 12, 2021 at 5:30 PM UTC

The latest signal of Bayer’s growing interest in gene and cell therapies is its investment in synthetic biology company Senti, whose gene circuit technology gives the biotech both an internal pipeline and a partnering opportunity.

The pharma’s Leaps by Bayer venture arm led a $105 million series B round Wednesday for Senti, which was co-founded by CEO Tim Lu...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Bayer AG

Senti Biosciences Inc.